JPWO2019172213A1 - Nanoparticles, methods for producing nanoparticles, and antitumor agents - Google Patents
Nanoparticles, methods for producing nanoparticles, and antitumor agents Download PDFInfo
- Publication number
- JPWO2019172213A1 JPWO2019172213A1 JP2020505032A JP2020505032A JPWO2019172213A1 JP WO2019172213 A1 JPWO2019172213 A1 JP WO2019172213A1 JP 2020505032 A JP2020505032 A JP 2020505032A JP 2020505032 A JP2020505032 A JP 2020505032A JP WO2019172213 A1 JPWO2019172213 A1 JP WO2019172213A1
- Authority
- JP
- Japan
- Prior art keywords
- nanoparticles
- core
- shell
- glucose
- mfe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 163
- 239000002246 antineoplastic agent Substances 0.000 title claims description 7
- 238000000034 method Methods 0.000 title description 10
- 239000011258 core-shell material Substances 0.000 claims abstract description 69
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 40
- 150000002303 glucose derivatives Chemical class 0.000 claims abstract description 36
- 239000008103 glucose Substances 0.000 claims abstract description 33
- 150000003624 transition metals Chemical class 0.000 claims abstract description 21
- 229910052723 transition metal Inorganic materials 0.000 claims abstract description 19
- 125000000524 functional group Chemical group 0.000 claims abstract description 14
- 238000004519 manufacturing process Methods 0.000 claims description 23
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 19
- 229920001515 polyalkylene glycol Polymers 0.000 claims description 17
- 229910021486 amorphous silicon dioxide Inorganic materials 0.000 claims description 15
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- 238000010304 firing Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 6
- 229910052742 iron Inorganic materials 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 3
- 230000001590 oxidative effect Effects 0.000 claims description 3
- 239000000376 reactant Substances 0.000 claims description 3
- 125000005647 linker group Chemical group 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 2
- 229910000708 MFe2O4 Inorganic materials 0.000 abstract 2
- 238000005259 measurement Methods 0.000 description 48
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 32
- 239000002245 particle Substances 0.000 description 25
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 24
- 229910003321 CoFe Inorganic materials 0.000 description 22
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 18
- 238000002441 X-ray diffraction Methods 0.000 description 17
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 16
- 238000006243 chemical reaction Methods 0.000 description 16
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 239000011164 primary particle Substances 0.000 description 11
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 10
- 229960002442 glucosamine Drugs 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 229920001223 polyethylene glycol Polymers 0.000 description 9
- 239000000243 solution Substances 0.000 description 8
- 229910004298 SiO 2 Inorganic materials 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 7
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 6
- 239000010419 fine particle Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000011163 secondary particle Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 206010020843 Hyperthermia Diseases 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
- 230000036031 hyperthermia Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 238000007385 chemical modification Methods 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 239000000696 magnetic material Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000006386 neutralization reaction Methods 0.000 description 4
- 230000021523 carboxylation Effects 0.000 description 3
- 238000006473 carboxylation reaction Methods 0.000 description 3
- QRXDDLFGCDQOTA-UHFFFAOYSA-N cobalt(2+) iron(2+) oxygen(2-) Chemical compound [O-2].[Fe+2].[Co+2].[O-2] QRXDDLFGCDQOTA-UHFFFAOYSA-N 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229910052596 spinel Inorganic materials 0.000 description 3
- 239000011029 spinel Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 229910000859 α-Fe Inorganic materials 0.000 description 3
- SDGKUVSVPIIUCF-UHFFFAOYSA-N 2,6-dimethylpiperidine Chemical compound CC1CCCC(C)N1 SDGKUVSVPIIUCF-UHFFFAOYSA-N 0.000 description 2
- -1 COC Natural products 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- 238000001354 calcination Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 229910017052 cobalt Inorganic materials 0.000 description 2
- 239000010941 cobalt Substances 0.000 description 2
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 2
- 239000002122 magnetic nanoparticle Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 229930195734 saturated hydrocarbon Natural products 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- CBOJBBMQJBVCMW-BTVCFUMJSA-N (2r,3r,4s,5r)-2-amino-3,4,5,6-tetrahydroxyhexanal;hydrochloride Chemical compound Cl.O=C[C@H](N)[C@@H](O)[C@H](O)[C@H](O)CO CBOJBBMQJBVCMW-BTVCFUMJSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000006087 Silane Coupling Agent Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000004455 differential thermal analysis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001911 glucosamine hydrochloride Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000005381 magnetic domain Effects 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical compound [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- JXUKBNICSRJFAP-UHFFFAOYSA-N triethoxy-[3-(oxiran-2-ylmethoxy)propyl]silane Chemical compound CCO[Si](OCC)(OCC)CCCOCC1CO1 JXUKBNICSRJFAP-UHFFFAOYSA-N 0.000 description 1
- 239000011882 ultra-fine particle Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compounds Of Iron (AREA)
Abstract
このナノ微粒子（１）は、ＭＦｅ２Ｏ４からなるコア（１０）（Ｍは遷移金属を表す）と、コア（１０）を覆うシェル（２０）と、を有し、シェル（２０）がグルコース又はグルコース誘導体Ｇｌｃ’で化学修飾されている。Ｘは２価の連結基である。このナノ微粒子（１）は、ＭＦｅ２Ｏ４からなるコア（１０）と、コア（１０）を覆う官能基を含むシェルと、を有するコアシェル型ナノ微粒子を形成する工程と、前記官能基にグルコース又はグルコース誘導体を反応させる工程とにより製造することができる。［化１］The nanoparticles (1) have a core (10) composed of MFe2O4 (where M represents a transition metal) and a shell (20) covering the core (10), wherein the shell (20) is glucose or a glucose derivative. It is chemically modified with Glc'. X is a divalent linking group. The nanoparticles (1) have a step of forming core-shell type nanoparticles having a core (10) made of MFe2O4 and a shell containing a functional group covering the core (10), and glucose or a glucose derivative on the functional groups. Can be produced by the step of reacting. [Chemical 1]
Description
本発明は、ナノ微粒子、及びナノ微粒子の製造方法、このナノ微粒子を有効成分として含有する抗腫瘍剤、並びにこのナノ微粒子を製造するためのコアシェル型ナノ微粒子の製造方法に関する。
本願は、２０１８年３月５日に、日本に出願された特願２０１８−０３８９８９号に基づき優先権を主張し、その内容をここに援用する。The present invention relates to nanoparticles and a method for producing the nanoparticles, an antitumor agent containing the nanoparticles as an active ingredient, and a method for producing core-shell type nanoparticles for producing the nanoparticles.
The present application claims priority based on Japanese Patent Application No. 2018-038989 filed in Japan on March 5, 2018, the contents of which are incorporated herein by reference.
ナノメートルスケールの超微粒子であるナノ微粒子は、従来にない新たな特異な物性をもたらし、機能材料としての高性能化が期待できることから、種々の物質について検討がされている。特に、磁性材料を微粒子化すると、磁壁を持たない単磁区粒子が生じ、保磁力が大きくなることが期待されている。 Nanoparticles, which are nanometer-scale ultrafine particles, bring about new and unique physical properties that have never existed before, and are expected to have higher performance as functional materials. Therefore, various substances have been studied. In particular, when the magnetic material is made into fine particles, it is expected that single magnetic domain particles having no domain wall will be generated and the coercive force will be increased.
本発明者らは、表面をＳｉＯ２により被覆されたマグネタイト等の磁気ナノ微粒子の調製に成功しており、このＳｉＯ２を介して官能基を導入した技術を報告している（特許文献１、２参照）。この官能基により、磁気微粒子への薬剤等の修飾や、細胞、組織内へ磁気微粒子を容易に取り込むことが可能である。The present inventors have found that the surface has been successful in the preparation of the magnetic nanoparticles of magnetite coated with SiO 2, and have reported a technique of introducing a functional group through the SiO 2 (Patent Document 1, 2). With this functional group, it is possible to modify the magnetic fine particles with a drug or the like and easily take the magnetic fine particles into cells and tissues.
一方、がん細胞は正常細胞に比べて単位時間当たり３〜８倍のグルコースを取り込むことが知られている。また、ＥＰＲ効果、すなわち、がん細胞の周りの血管壁は高分子薬剤を透過しやすく、透過した高分子薬剤は腫瘍組織中あるいはその周辺に集積しやすいことも知られている。 On the other hand, cancer cells are known to take up 3 to 8 times more glucose per unit time than normal cells. It is also known that the EPR effect, that is, the blood vessel wall around the cancer cell easily permeates the polymer drug, and the permeated polymer drug easily accumulates in or around the tumor tissue.
ナノ微粒子の表面に、グルコースに近似した構造を導入することができれば、腫瘍組織中あるいはその周辺に集積しやすい性質が得られると期待できる。 If a structure similar to glucose can be introduced on the surface of the nanoparticles, it can be expected that the property of easily accumulating in or around the tumor tissue can be obtained.
本発明は、グルコース又はグルコース誘導体で化学修飾されたナノ微粒子、及びその製造方法、このナノ微粒子を有効成分として含有する抗腫瘍剤、並びにこのナノ微粒子を製造するためのコアシェル型ナノ微粒子の製造方法を提供することを課題とする。 The present invention relates to nanoparticles chemically modified with glucose or a glucose derivative, a method for producing the same, an antitumor agent containing the nanoparticles as an active ingredient, and a method for producing core-shell type nanoparticles for producing the nanoparticles. The challenge is to provide.
本発明は、以下の態様を有する。
［１］ ＭＦｅ２Ｏ４からなるコア（前記ＭＦｅ２Ｏ４において、Ｍは遷移金属を表す）と、
前記コアを覆うシェルと、を有し、
前記シェルがグルコース又はグルコース誘導体で化学修飾されているナノ微粒子。The present invention has the following aspects.
[1] A core composed of MFe 2 O 4 (in MFe 2 O 4 above, M represents a transition metal) and
With a shell covering the core,
Nanoparticles in which the shell is chemically modified with glucose or a glucose derivative.
［２］ 前記シェルがグルコース又はグルコース誘導体で化学修飾されたポリアルキレングリコールからなる、前記［１］に記載のナノ微粒子。 [2] The nanoparticles according to the above [1], wherein the shell is made of glucose or a polyalkylene glycol chemically modified with a glucose derivative.
［３］ 前記シェルがグルコース又はグルコース誘導体で化学修飾されたアモルファスＳｉＯ２からなる、前記［１］に記載のナノ微粒子。[3] The nanoparticles according to the above [1], wherein the shell is composed of amorphous SiO 2 chemically modified with glucose or a glucose derivative.
［４］ 前記グルコース誘導体がアミノ基を有する、前記［１］〜［３］のうちいずれか一項に記載のナノ微粒子。 [4] The nanoparticles according to any one of the above [1] to [3], wherein the glucose derivative has an amino group.
［５］ ＭＦｅ２Ｏ４からなるコア（前記ＭＦｅ２Ｏ４において、Ｍは遷移金属を表す）と、前記コアを覆う官能基を含むシェルと、を有するコアシェル型ナノ微粒子を形成する工程と、
前記官能基にグルコース又はグルコース誘導体を反応させる工程と、を有する、前記［１］〜［４］のうちいずれか一項に記載のナノ微粒子の製造方法。[5] A step of forming core-shell type nanoparticles having a core composed of MFe 2 O 4 (in the MFe 2 O 4 , M represents a transition metal) and a shell containing a functional group covering the core.
The method for producing nanoparticles according to any one of the above [1] to [4], which comprises a step of reacting a glucose or a glucose derivative with the functional group.
［６］ ＭＦｅ２Ｏ４からなるコア（前記ＭＦｅ２Ｏ４において、Ｍは遷移金属を表す）と、前記コアを覆うポリアルキレングリコールからなるシェルと、を有するコアシェル型ナノ微粒子を形成する工程と、
前記ポリアルキレングリコールの末端のヒドロキシメチル基を酸化させて、カルボキシル基にする工程と、
前記カルボキシル基にグルコース又はグルコース誘導体を反応させる工程と、を有する、前記［５］に記載のナノ微粒子の製造方法。[6] (in the MFe 2 O 4, M represents a transition metal) MFe 2 core consisting of O 4 forming the, core-shell nanoparticles having a shell of a polyalkylene glycol to cover the core ,
The step of oxidizing the hydroxymethyl group at the terminal of the polyalkylene glycol to form a carboxyl group, and
The method for producing nanoparticles according to the above [5], which comprises a step of reacting a glucose or a glucose derivative with the carboxyl group.
［７］ 前記［１］〜［４］のうちいずれか一項に記載のナノ微粒子を有効成分として含有する抗腫瘍剤。
［８］ ポリアルキレングリコール、鉄を含む遷移金属の塩化物、及びアルカリを加熱し混合して、水酸化物を得る工程と、
前記水酸化物を含む反応物を加熱し焼成する工程と、を有するコアシェル型ナノ微粒子の製造方法。[7] An antitumor agent containing the nanoparticles according to any one of the above [1] to [4] as an active ingredient.
[8] A step of heating and mixing polyalkylene glycol, a chloride of a transition metal containing iron, and an alkali to obtain a hydroxide.
A method for producing core-shell type nanoparticles, which comprises a step of heating and firing a reactant containing a hydroxide.
本発明は、ナノ微粒子、及びナノ微粒子の製造方法、このナノ微粒子を有効成分として含有する抗腫瘍剤、並びにこのナノ微粒子を製造するためのコアシェル型ナノ微粒子の製造方法を提供する。本発明のナノ微粒子は、シェルがグルコース又はグルコース誘導体で化学修飾されているので、腫瘍組織中に集積しやすい性質が得られると期待できる。また、本発明のナノ微粒子は、ＭＦｅ２Ｏ４からなるコアを有しているので、磁気ハイパーサーミア（癌温熱療法）への利用も期待できる。The present invention provides nanoparticles and a method for producing nanoparticles, an antitumor agent containing the nanoparticles as an active ingredient, and a method for producing core-shell type nanoparticles for producing the nanoparticles. Since the shell of the nanoparticles of the present invention is chemically modified with glucose or a glucose derivative, it can be expected that the nanoparticles have a property of easily accumulating in tumor tissue. Further, since the nanoparticles of the present invention have a core composed of MFe 2 O 4, they can be expected to be used for magnetic hyperthermia (cancer hyperthermia).
≪ナノ微粒子≫
以下、本発明の実施形態について説明する。
本実施形態のナノ微粒子は、ＭＦｅ２Ｏ４からなるコア（前記ＭＦｅ２Ｏ４において、Ｍは遷移金属を表す）と、前記コアを覆うシェルと、を有し、前記シェルがグルコース又はグルコース誘導体で化学修飾されている。≪Nanofine particles≫
Hereinafter, embodiments of the present invention will be described.
The nanoparticles of the present embodiment have a core composed of MFe 2 O 4 (in MFe 2 O 4 , M represents a transition metal) and a shell covering the core, and the shell is glucose or a glucose derivative. It is chemically modified with.
下記式（１）のナノ微粒子１は、本実施形態のナノ微粒子の構造の一例である。ナノ微粒子１は、ＭＦｅ２Ｏ４からなるコア１０（Ｍは遷移金属を表す）と、コア１０を覆うシェル２０と、を有し、シェル２０が２価の連結基Ｘを介してグルコース誘導体Ｇｌｃ’で化学修飾されている。Ｘは２価の連結基である。The nanoparticles 1 of the following formula (1) is an example of the structure of the nanoparticles of the present embodiment. The nanoparticles 1 have a core 10 composed of MFe 2 O 4 (M represents a transition metal) and a shell 20 covering the core 10, and the shell 20 has a glucose derivative Glc via a divalent linking group X. It is chemically modified with'. X is a divalent linking group.
ここで、グルコース誘導体Ｇｌｃ’とは、グルコース骨格を有する化合物をいう。グルコース誘導体Ｇｌｃ’としてアミノ基を有するグルコース誘導体が好ましい。グルコース誘導体Ｇｌｃ’の具体例として、グルコサミンが挙げられる。 Here, the glucose derivative Glc'refers to a compound having a glucose skeleton. A glucose derivative having an amino group is preferable as the glucose derivative Glc'. Specific examples of the glucose derivative Glc' include glucosamine.
式（１）のナノ微粒子１のうち、シェルがグルコサミンで化学修飾されたものとして、下記式（１−１）で表されるナノ微粒子が挙げられる。 Among the nanoparticles 1 of the formula (1), those in which the shell is chemically modified with glucosamine include the nanoparticles represented by the following formula (1-1).
下記式（２）のナノ微粒子２は、本実施形態のナノ微粒子の構造の一例である。ナノ微粒子２は、ＭＦｅ２Ｏ４からなるコア１０（Ｍは遷移金属を表す）と、コア１０を覆うシェル２０と、を有し、シェル２０が２価の連結基Ｘを介してグルコースで化学修飾されている。Ｘは２価の連結基である。The nanoparticles 2 of the following formula (2) are an example of the structure of the nanoparticles of the present embodiment. The nanoparticles 2 have a core 10 composed of MFe 2 O 4 (where M represents a transition metal) and a shell 20 covering the core 10, where the shell 20 is chemically treated with glucose via a divalent link X. It is qualified. X is a divalent linking group.
式（２）のナノ微粒子２の具体例としては、下記式（２−１）、式（２−２）、式（２−３）で表されるナノ微粒子が挙げられる。 Specific examples of the nanoparticles 2 of the formula (2) include nanoparticles represented by the following formulas (2-1), formula (2-2), and formula (2-3).
（シェル）
コアを覆うシェルはグルコース又はグルコース誘導体で化学修飾されている。シェルはコアの全部を覆うものであってもよく、部分的に覆うものであっていてもよい。シェルの内部に２個以上のコアを包摂した包摂構造を形成していてもよい。(shell)
The shell covering the core is chemically modified with glucose or a glucose derivative. The shell may cover the entire core or may partially cover it. An inclusion structure may be formed in which two or more cores are included inside the shell.
本実施形態のナノ微粒子において、ＭＦｅ２Ｏ４からなるコアが、シェルで覆われていることは、微粒子に対してグルコース又はグルコース誘導体を化学修飾する反応工程を経た後、グルコース又はグルコース誘導体が反応性のシェルに化学修飾されたことで確認することができる。In the nanoparticles of the present embodiment, the fact that the core composed of MFe 2 O 4 is covered with a shell means that the glucose or glucose derivative reacts after undergoing a reaction step of chemically modifying glucose or a glucose derivative with respect to the fine particles. It can be confirmed by the chemical modification of the sex shell.
シェルとなる材料は、グルコース又はグルコース誘導体で化学修飾され得るものであればよく、ポリアルキレングリコールからなるものであってもよい。ポリアルキレングリコールをシェルとするナノ微粒子は、例えば、後述する「コアシェル型ナノ微粒子の製造方法」により製造することができる。 The material used as the shell may be any material that can be chemically modified with glucose or a glucose derivative, and may be made of polyalkylene glycol. The nanoparticles having polyalkylene glycol as a shell can be produced, for example, by the "method for producing core-shell type nanoparticles" described later.
シェルとなる材料は、アモルファスＳｉＯ２からなるものであってもよく、シェルは、コアを覆うアモルファスＳｉＯ２ネットワーク（網状膜）を形成していてもよい。例えば、アモルファスＳｉＯ２の網状膜によって、コアが分離された状態であってもよい。ここで「網状膜」とは、アモルファスＳｉＯ２が個々のコアの周囲を取り囲み、且つアモルファスＳｉＯ２が連なっているものが例示されるが、これに限定されない。The material used as the shell may be made of amorphous SiO 2 , and the shell may form an amorphous SiO 2 network (reticular membrane) covering the core. For example, the core may be separated by a reticular membrane of amorphous SiO 2 . Here, the "reticular membrane" amorphous SiO 2 surrounds the periphery of the individual cores, but and those amorphous SiO 2 are continuous are exemplified, but not limited thereto.
なお、ナノ微粒子のコアが、アモルファスＳｉＯ２からなるシェルで覆われていることの確認は、Ｘ線回折によりアモルファスＳｉＯ２とマグネタイトの回折線が観測されること、及びナノ微粒子の一次粒子径が上記Ｘ線回折の半値幅から予想される程度の値であること、からも行うことができる。The core of the nanoparticles is, confirmation that is covered with a shell made of amorphous SiO 2 is that the amorphous SiO 2 and a diffraction line of magnetite is observed by X-ray diffraction, and the primary particle diameter of nanoparticles It can also be performed from the fact that the value is about the value expected from the half price range of the X-ray diffraction.
（コア）
本実施形態に係るコアは、ＭＦｅ２Ｏ４からなる。本実施形態に係るナノ微粒子のコアとしてフェライトを採用することで、磁性材料としての利用が可能となる。
前記ＭＦｅ２Ｏ４において、Ｍは遷移金属を表す。遷移金属としては、イオン化したときに２価になるものが好ましく、例えば、Ｃｒ、Ｍｎ、Ｆｅ、Ｃｏ、Ｎｉ、Ｃｕ、Ｚｎが挙げられる。また、これらの遷移金属を２種以上併せて用いても良い。前記ＭがＦｅである場合、ＭＦｅ２Ｏ４は、例えばＦｅ３Ｏ４である。これらのなかでも、ＭはＣｏであることが好ましい。また、２種以上併せて用いる場合には、ＭｎＺｎが好ましい。(core)
The core according to this embodiment is made of MFe 2 O 4 . By adopting ferrite as the core of the nanoparticles according to the present embodiment, it can be used as a magnetic material.
In the MFe 2 O 4 , M represents a transition metal. The transition metal preferably becomes divalent when ionized, and examples thereof include Cr, Mn, Fe, Co, Ni, Cu, and Zn. Further, two or more of these transition metals may be used in combination. When M is Fe, MFe 2 O 4 is, for example, Fe 3 O 4 . Among these, M is preferably Co. Further, when two or more kinds are used together, MnZn is preferable.
（アモルファスＳｉＯ２をシェルとするナノ微粒子）
本実施形態に係るナノ微粒子は、前記コアとそれを覆うシェルとを有し、前記シェルがグルコース又はグルコース誘導体で化学修飾されたアモルファスＳｉＯ２からなるからなるものであってもよい。アモルファスＳｉＯ２に対しては、例えば、３−イソシアネートプロピルトリエトキシシランシラン、３−グリシドキシプロピルトリエトキシシラン等のカップリング剤を用いて、式（２−１）、式（２−２）で表されるナノ微粒子のように、グルコース又はグルコース誘導体を化学修飾することができる。(Nanofine particles with amorphous SiO 2 as a shell)
The nanoparticles according to the present embodiment may have the core and a shell covering the core, and the shell may be made of amorphous SiO 2 chemically modified with glucose or a glucose derivative. For amorphous SiO 2 , for example, a coupling agent such as 3-isocyanatepropyltriethoxysilanesilane or 3-glycidoxypropyltriethoxysilane is used, and the formulas (2-1) and (2-2) are used. Propyl or a glucose derivative can be chemically modified, such as the nanoparticles represented by.
シェルは、コアを覆うアモルファスＳｉＯ２ネットワーク（網状膜）を形成していてもよい。本実施形態に係るナノ微粒子は、シェルの内部に２個以上のコアを包摂した包摂構造を形成していてもよい。The shell may form an amorphous SiO 2 network (reticular membrane) covering the core. The nanoparticles according to the present embodiment may form an inclusion structure in which two or more cores are included inside the shell.
アモルファスＳｉＯ２をシェルとするナノ微粒子において、前記ＭＦｅ２Ｏ４に対する前記ＳｉＯ２のモル比（ＳｉＯ２／ＭＦｅ２Ｏ４）は、０．１以上５以下であることが好ましく、０．３以上４以下であることがより好ましく、０．４以上２以下であることがさらに好ましい。ＳｉＯ２／ＭＦｅ２Ｏ４が０．１以上５以下であることが好ましい。また、ＳｉＯ２／ＭＦｅ２Ｏ４が上記範囲内の値であると、ナノ微粒子の分散性に優れるため好ましい。In nanoparticles of amorphous SiO 2 and the shell, the MFe 2 O 4 molar ratio of the SiO 2 to (SiO 2 / MFe 2 O 4 ) is preferably 0.1 to 5, 0.3 or higher It is more preferably 4 or less, and further preferably 0.4 or more and 2 or less. It is preferable that SiO 2 / MFe 2 O 4 is 0.1 or more and 5 or less. Further, when SiO 2 / MFe 2 O 4 is a value within the above range, it is preferable because the dispersibility of the nanoparticles is excellent.
≪ナノ微粒子の製造方法の製造方法≫
本実施形態のナノ微粒子は、例えば、ＭＦｅ２Ｏ４からなるコア（前記ＭＦｅ２Ｏ４において、Ｍは遷移金属を表す）と、前記コアを覆う官能基を含むシェルと、を有するコアシェル型ナノ微粒子を形成する工程と、前記官能基にグルコース又はグルコース誘導体を反応させる工程と、を有する方法に沿って製造できる。≪Manufacturing method of manufacturing method of nanoparticles≫
Nanoparticles of the present embodiment, for example, (in the MFe 2 O 4, M represents a transition metal) core made of MFe 2 O 4 core-shell nano with a, a, a shell comprising a functional group that covers the core It can be produced according to a method having a step of forming fine particles and a step of reacting the functional group with glucose or a glucose derivative.
コアシェル型ナノ微粒子を形成する工程は、特許文献１（特開２００１−２６１３３４号公報）や特許文献２（特開２００７−２６９７７０号公報）に沿った方法を採用することができ、後述する≪コアシェル型ナノ微粒子の製造方法≫において説明された方法を採用することができる。特許文献１（特開２００１−２６１３３４号公報）や特許文献２（特開２００７−２６９７７０号公報）に沿った方法で形成した、表面をＳｉＯ２により被覆されたナノ微粒子では、さらに、グルコース又はグルコース誘導体で化学修飾し易いように、シランカップリング剤で官能基を導入してもよい。As a step of forming core-shell type nanoparticles, a method according to Patent Document 1 (Japanese Patent Laid-Open No. 2001-261334) and Patent Document 2 (Japanese Patent Laid-Open No. 2007-269770) can be adopted. The method described in the method for producing type nanoparticles >> can be adopted. In the nanoparticles whose surface is coated with SiO 2 , which is formed by the method according to Patent Document 1 (Japanese Patent Laid-Open No. 2001-261334) and Patent Document 2 (Japanese Patent Laid-Open No. 2007-269770), glucose or glucose is further added. A functional group may be introduced with a silane coupling agent so that it can be easily chemically modified with a derivative.
後述する≪コアシェル型ナノ微粒子の製造方法≫に沿った方法で形成した、表面に−ＣＨ２ＯＨ基を有するコアシェル型ナノ微粒子では、さらに、下記式（３）に示されるように、−ＣＨ２ＯＨ基を酸化して、表面に−ＣＯＯＨ基を有するコアシェル型ナノ微粒子としてもよい。It was formed by a method in line with the «production method of core-shell nanoparticles» which will be described later, in the core-shell nanoparticles having a -CH 2 OH group on the surface, further, as shown in the following formula (3), -CH 2 The OH group may be oxidized to form core-shell type nanoparticles having a -COOH group on the surface.
このコアシェル型ナノ微粒子を用いるナノ微粒子の製造方法は、一例として、ＭＦｅ２Ｏ４からなるコア（前記ＭＦｅ２Ｏ４において、Ｍは遷移金属を表す）と、前記コアを覆うポリアルキレングリコールからなるシェルと、を有するコアシェル型ナノ微粒子を形成する工程と、前記ポリアルキレングリコールの末端のヒドロキシメチル基を酸化させて、カルボキシル基にする工程と、前記カルボキシル基にグルコース又はグルコース誘導体を反応させる工程と、を有する。Method for producing nanoparticles using the core-shell type nanoparticles, as an example, (in the MFe 2 O 4, M represents a transition metal) core made of MFe 2 O 4 and consists of a polyalkylene glycol to cover the core A step of forming a core-shell type nanoparticles having a shell, a step of oxidizing a hydroxymethyl group at the terminal of the polyalkylene glycol to form a carboxyl group, and a step of reacting the carboxyl group with glucose or a glucose derivative. , Have.
前記官能基にグルコース又はグルコース誘導体を反応させる工程は、官能基とグルコース又はグルコース誘導体との組み合わせに応じて、公知の方法で行うことができる。例えば、前記官能基がカルボキシル基であって、前記グルコース誘導体がグルコサミンであるとき、前記カルボキシル基にグルコース誘導体を反応させる工程は、下記式（４）で示すことができる。 The step of reacting the functional group with glucose or a glucose derivative can be carried out by a known method depending on the combination of the functional group and glucose or the glucose derivative. For example, when the functional group is a carboxyl group and the glucose derivative is glucosamine, the step of reacting the glucose derivative with the carboxyl group can be represented by the following formula (4).
≪コアシェル型ナノ微粒子の製造方法≫
本実施形態のコアシェル型ナノ微粒子の製造方法は、ポリアルキレングリコール、鉄を含む遷移金属の塩化物、及びアルカリを加熱し混合して、水酸化物を得る工程と、
前記水酸化物を含む反応物を加熱し焼成する工程と、を有する。≪Manufacturing method of core-shell type nanoparticles≫
The method for producing core-shell type nanoparticles of the present embodiment includes a step of heating and mixing polyalkylene glycol, a chloride of a transition metal containing iron, and an alkali to obtain a hydroxide.
It has a step of heating and calcining the reaction product containing the hydroxide.
ポリアルキレングリコールとしては、ポリエチレングリコール、ポリプロピレングリコール等を挙げることができる。これらのポリアルキレングリコールの質量平均分子量は２００〜８０００であるものが好ましく、３００〜２０００であるものがより好ましい。例えば、質量平均分子量が約３８０〜４２０の市販のＰＥＧ４００、質量平均分子量が約５６０〜６４０の市販のＰＥＧ６００、質量平均分子量が約９００〜１１００の市販のＰＥＧ１０００、質量平均分子量が１８５０〜２１５０の市販のＰＥＧ２０００、質量平均分子量が約４００の市販のＰＰＧ４００、等を用いることができる。ＰＥＧ２０００を用いると立体障害が大きいため、コアシェル型ナノ微粒子の分散性が良くなると考えられる。 Examples of the polyalkylene glycol include polyethylene glycol and polypropylene glycol. The mass average molecular weight of these polyalkylene glycols is preferably 200 to 8000, more preferably 300 to 2000. For example, a commercially available PEG400 having a mass average molecular weight of about 380 to 420, a commercially available PEG600 having a mass average molecular weight of about 560 to 640, a commercially available PEG1000 having a mass average molecular weight of about 900 to 1100, and a commercially available mass average molecular weight of 1850 to 2150. PEG2000, a commercially available PPG400 having a mass average molecular weight of about 400, and the like can be used. Since PEG2000 has a large steric hindrance, it is considered that the dispersibility of the core-shell type nanoparticles is improved.
鉄を含む遷移金属の塩化物としては、ＭＣｌ２・６Ｈ２Ｏ（Ｍは遷移金属を表す）、ＦｅＣｌ２・４Ｈ２Ｏの試薬を用いることができる。ＭＣｌ２・６Ｈ２Ｏ及びＦｅＣｌ２・４Ｈ２Ｏを、Ｍ：Ｆｅ＝１モル：２モルの比で混合して用いてもよく、ＦｅＣｌ２・４Ｈ２Ｏを単独で用いてもよい。The chlorides of transition metals, including iron, MCl 2 · 6H 2 O (where M represents a transition metal), may be used a reagent of FeCl 2 · 4H 2 O. MCl the 2 · 6H 2 O and FeCl 2 · 4H 2 O, M : Fe = 1 mole: may be used as a mixture with 2 moles of ratios may be used FeCl 2 · 4H 2 O alone.
ポリアルキレングリコール、鉄を含む遷移金属の塩化物、及びアルカリを加熱し混合すると、中和反応し、水酸化物を得ることができる。中和反応の温度としては、４０〜１００℃が好ましく、６０〜８０℃が好ましい。中和反応の時間は、３０分〜２時間が好ましい。さらに、水酸化物を含む反応物を加熱し焼成することで、コアシェル型ナノ微粒子を液体のポリアルキレングリコール中に沈殿させることができる。焼成温度は、１２０〜２８０℃が好ましく、１６０〜２２０℃がより好ましい。焼成時間は３時間以上とすることが好ましい。 When polyalkylene glycol, chloride of a transition metal containing iron, and alkali are heated and mixed, a neutralization reaction can be obtained to obtain a hydroxide. The temperature of the neutralization reaction is preferably 40 to 100 ° C, preferably 60 to 80 ° C. The neutralization reaction time is preferably 30 minutes to 2 hours. Further, by heating and calcining the reactant containing the hydroxide, the core-shell type nanoparticles can be precipitated in the liquid polyalkylene glycol. The firing temperature is preferably 120 to 280 ° C, more preferably 160 to 220 ° C. The firing time is preferably 3 hours or more.
本実施形態のコアシェル型ナノ微粒子の磁性体部分の体積平均粒子径は、１ｎｍ以上５０ｎｍ以下であることが好ましく、２ｎｍ以上２０ｎｍ以下であることがより好ましい。
ここで、体積平均粒子径は、コアシェル型ナノ微粒子の１個のコアの磁性体部分に対して求められた一次粒子径である。体積平均粒子径は算術平均径である。
コアシェル型ナノ微粒子のコアの磁性体部分の体積平均粒子径は、Ｘ線回折（ＸＲＤ）により求めることができる。The volume average particle diameter of the magnetic material portion of the core-shell type nanoparticles of the present embodiment is preferably 1 nm or more and 50 nm or less, and more preferably 2 nm or more and 20 nm or less.
Here, the volume average particle diameter is the primary particle diameter obtained for the magnetic material portion of one core of the core-shell type nanoparticles. The volume average particle diameter is the arithmetic mean diameter.
The volume average particle diameter of the magnetic part of the core of the core-shell type nanoparticles can be determined by X-ray diffraction (XRD).
上記コアシェル型ナノ微粒子を、上記水溶液を混合し焼成して製造する場合、焼成温度が高くなるほど、又焼成時間が長いほど、コアシェル型ナノ微粒子が成長して粒径が大きくなるので、焼成温度又は焼成時間を調整することで、コアシェル型ナノ微粒子の粒径を制御できる。 When the core-shell type nanoparticles are produced by mixing the above aqueous solution and firing, the higher the firing temperature and the longer the firing time, the larger the core-shell type nanoparticles grow and the larger the particle size. By adjusting the firing time, the particle size of the core-shell type nanoparticles can be controlled.
以下、具体的実施例により、本発明についてさらに詳しく説明する。ただし、本発明は、以下に示す実施例に何ら限定されるものではない。 Hereinafter, the present invention will be described in more detail with reference to specific examples. However, the present invention is not limited to the examples shown below.
＜ＸＲＤ分析＞
粉末Ｘ線回折測定機器（リガク：ＭｉｎｉＦｌｅｘ ＩＩ）を用いてＸＲＤ分析を行った。<XRD analysis>
XRD analysis was performed using a powder X-ray diffraction measuring device (Rigaku: MiniFlex II).
＜平均粒径（一次粒子径）の測定＞
粉末Ｘ線回折測定機器（リガク：ＭｉｎｉＦｌｅｘ ＩＩ）を用いて、コアシェル型ナノ微粒子の磁性体部分の平均粒径（一次粒子径）を測定した。数値は、Ｃｒｙｓｔａｌ Ｓｉｚｅ Ｄｉｓｔｒｉｂｕｔｉｏｎ Ａｎａｌｙｓｉｓ（ＣＳＤＡ）を用いて体積平均粒子径として算出した。<Measurement of average particle size (primary particle size)>
The average particle size (primary particle size) of the magnetic part of the core-shell type nanoparticles was measured using a powder X-ray diffraction measuring device (Rigaku: MiniFlex II). The numerical value was calculated as a volume average particle size using Crystal Size Distribution Analysis (CSDA).
＜ＭＳ測定＞
ＤＨＢをマトリクスとして、Ａｕｔｏｆｌｅｘ ｓｐｅｅｄ−ＴＯＦ−ＭＳ装置（Ｂｒｕｋｅｒ Ｄａｌｔｏｎｉｃｓ）により、ナノ微粒子の質量分析測定を行った。装置の仕様を以下に示す。
レーザー周波数； １ｋ Ｈｚ
質量分解能（ＦＷＨＭ）； Ｍａｘ： ２５００
質量精度 ； ｍｉｎ： ２ ｐｐｍ
レーザー焦点径；ｍａｘ： １０ μｍ
レーザー； Ｎｄ：Ｙａｇ ｌａｓｅｒ （３５５ ｎｍ）
最大パワー ＜１７０ｋＷ
パルスエネルギー ＜５００μＪ
パルス幅 ＞３ｎｓ
平均パワー ＜１．５Ｗ<MS measurement>
Using DHB as a matrix, mass spectrometric measurement of nanoparticles was performed by an Autoflex speed-TOF-MS apparatus (Bruker Daltonics). The specifications of the device are shown below.
Laser frequency; 1 kHz
Mass resolution (FWHM); Max: 2500
Mass accuracy; min: 2 ppm
Laser focal diameter; max: 10 μm
Laser; Nd: Yag laser (355 nm)
Maximum power <170kW
Pulse energy <500 μJ
Pulse width> 3ns
Average power <1.5W
＜二次粒径（モード径及びメジアン径）の測定＞
得られたナノ微粒子について、レーザー回折・散乱型粒度分布計（堀場製作所製：ＬＡ−９５０Ｖ２）を用いて水溶液中におけるナノ微粒子の粒度分布から、二次粒径（モード径及びメジアン径）を測定した。サンプルは全て水溶液中に分散させ、超音波処理にて分散処理を行った後、循環系にて測定を行った。装置の概要を以下に示す。<Measurement of secondary particle size (mode diameter and median diameter)>
For the obtained nanoparticles, measure the secondary particle size (mode diameter and median diameter) from the particle size distribution of the nanoparticles in the aqueous solution using a laser diffraction / scattering type particle size distribution meter (manufactured by HORIBA, Ltd .: LA-950V2). did. All the samples were dispersed in an aqueous solution, dispersed by ultrasonic treatment, and then measured in a circulatory system. The outline of the device is shown below.
堀場製作所製 ＬＡ−９５０Ｖ２
・測定原理： Ｍｉｅ散乱理論
・測定レンジ： ０．０１〜３０００ μｍ
・レーザー光源： 半導体レーザー（６５０ ｎｍ）
発光ダイオード（４０５ ｎｍ）
・検出器： リング上６４分割シリコンフォトダイオード×１個
４ｃｈアレイデテクタ×５個
シリコンフォトデテクタ×３個LA-950V2 manufactured by HORIBA, Ltd.
・ Measurement principle: Mie scattering theory ・ Measurement range: 0.01-3000 μm
-Laser light source: Semiconductor laser (650 nm)
Light emitting diode (405 nm)
・ Detector: 64 division silicon photodiode x 1 on the ring
4ch array detector x 5
Silicon photo detector x 3
［比較例１］
＜ナノ微粒子の作製＞
ＣｏＣｌ２・６Ｈ２Ｏ水溶液と、ＦｅＣｌ２・４Ｈ２Ｏ水溶液と、Ｎａ２ＳｉＯ３・９Ｈ２Ｏ水溶液をそれぞれモル比（ＣｏＣｌ２：ＦｅＣｌ２：Ｎａ２ＳｉＯ３＝１：２：３）で添加し、１５分間撹拌し、その後混合させ希釈したＮａＯＨを用いてｐＨを８．０に調整した。ｐＨ調整後の液をさらに１５分間撹拌し、遠心分離機により３５００ｒｐｍで１５分間遠心した後、上澄み液を除去し、沈殿物を純水にて洗浄する動作を３回繰り返した。約５０℃の恒温槽で約４０時間乾燥させた沈殿物を乳鉢にて粉砕した。その後、約８００℃で約１６時間焼成を行い、比較例のナノ微粒子試料を得た。ＸＲＤ分析の結果を図１（上）に示す。指数づけしたピークから、単相のスピネル構造を持ったＣｏＦｅ２Ｏ４ [No. 000-022-1086、Name: Cobalt Iron Oxide、Quality Mark: S、Cell (8.392, 8.392, 8.392)] が同定でき、２θ＝２０〜３０°の位置にアモルファスＳｉＯ２のブロードなピークが観察された。得られたナノ微粒子の組成は、ＣｏＦｅ２Ｏ４・３ＳｉＯ２であった。平均粒径（一次粒子径）は１０ｎｍであった。二次粒径は、モード径が３．６３μｍ、メジアン径は２．２７μｍであった。[Comparative Example 1]
<Preparation of nanoparticles>
CoCl and 2 · 6H 2 O aqueous solution, and FeCl 2 · 4H 2 O aqueous solution, respectively, a molar ratio Na 2 SiO 3 · 9H 2 O aqueous solution (CoCl 2: FeCl 2: Na 2 SiO 3 = 1: 2: 3) in The pH was adjusted to 8.0 with the addition, stirring for 15 minutes, then mixing and diluting NaOH. The pH-adjusted liquid was stirred for another 15 minutes, centrifuged at 3500 rpm for 15 minutes with a centrifuge, the supernatant was removed, and the precipitate was washed with pure water, which was repeated three times. The precipitate dried in a constant temperature bath at about 50 ° C. for about 40 hours was crushed in a mortar. Then, it was calcined at about 800 degreeC for about 16 hours, and the nanoparticle sample of a comparative example was obtained. The result of XRD analysis is shown in FIG. 1 (top). From the indexed peak, CoFe 2 O 4 [No. 000-022-1086, Name: Cobalt Iron Oxide, Quality Mark: S, Cell (8.392, 8.392, 8.392)] having a single-phase spinel structure can be identified. A broad peak of amorphous SiO 2 was observed at a position of 2θ = 20 to 30 °. The composition of the resulting nanoparticles was CoFe 2 O 4 · 3SiO 2. The average particle size (primary particle size) was 10 nm. The secondary particle size had a mode diameter of 3.63 μm and a median diameter of 2.27 μm.
［実施例１］
＜ＰＥＧ４００を用いたＣｏＦｅ２Ｏ４ナノ微粒子の作製＞
５０ｍｌのＰＥＧ４００の中で、５ｍｍｏｌのＦｅＣｌ２・４Ｈ２Ｏ、２．５ｍｍｏｌのＣｏＣｌ２・６Ｈ２Ｏ、及び１５ｍｍｏｌの水酸化ナトリウムを７０℃で１時間混合して、中和反応させた。反応液を、反応容器のまま箱型オーブンの中に入れ、２００℃で１６時間加熱し、炉冷後の反応液に対して、遠心分離機（３５００ｒｐｍ, １０ｍｉｎ）で沈殿させ、エタノールで三回洗浄する工程を３回繰り返した。乾燥して、ＣｏＦｅ２Ｏ４をコアとするコアシェル型ナノ微粒子の粉末を得た。得られたコアシェル型ナノ微粒子の磁性体部分の平均粒径（一次粒子径）は１２ｎｍであった。[Example 1]
<Preparation of CoFe 2 O 4 nanoparticles using PEG400>
Among 50ml of PEG 400, and mixed for 1 hour FeCl 2 · 4H 2 O in 5mmol, CoCl 2 · 6H 2 O of 2.5 mmol, and the sodium hydroxide 15mmol at 70 ° C., was neutralized reaction. The reaction solution is placed in a box-shaped oven as it is in the reaction vessel, heated at 200 ° C. for 16 hours, precipitated in the reaction solution after cooling in a furnace with a centrifuge (3500 rpm, 10 min), and three times with ethanol. The washing step was repeated 3 times. After drying, a powder of core-shell type nanoparticles having CoFe 2 O 4 as a core was obtained. The average particle size (primary particle size) of the magnetic part of the obtained core-shell type nanoparticles was 12 nm.
（ＸＲＤ分析結果）
ＸＲＤ分析の結果を図１（下）に示す。指数づけしたピークから、単相のスピネル構造を持ったＣｏＦｅ２Ｏ４ [No. 000-022-1086、Name: Cobalt Iron Oxide、Quality Mark: S、Cell (8.392, 8.392, 8.392)] が同定でき、不純物のピークを持たないことから、目的のＣｏＦｅ２Ｏ４が作成できた。湿式混合法で作ったＣｏＦｅ２Ｏ４をコアとするコアシェル型ナノ微粒子のＸＲＤ分析の結果の図１（上）に比べて、図１（下）のＰＥＧ４００を用いたコアシェル型ナノ微粒子のＸＲＤ分析の結果は、２０〜３０°の位置にアモルファスのブロードなピークがないことが確認された。(XRD analysis result)
The result of XRD analysis is shown in FIG. 1 (bottom). From the indexed peak, CoFe 2 O 4 [No. 000-022-1086, Name: Cobalt Iron Oxide, Quality Mark: S, Cell (8.392, 8.392, 8.392)] having a single-phase spinel structure can be identified. Since it does not have a peak of impurities, the desired CoFe 2 O 4 could be prepared. Compared with the result of XRD analysis of core-shell type nanoparticles having CoFe 2 O 4 as a core produced by the wet mixing method, XRD analysis of core-shell type nanoparticles using PEG400 in FIG. 1 (bottom). As a result, it was confirmed that there was no amorphous broad peak at the position of 20 to 30 °.
（ＦＴ−ＩＲ測定結果）
続いて、得られたコアシェル型ナノ微粒子のＦＴ−ＩＲ測定をした。実施例１のコアシェル型ナノ微粒子のＦＴ−ＩＲ測定結果を図２（上）に示す。ＣｏＦｅ２Ｏ４標準試料のＦＴ−ＩＲ測定結果を図２（下）に示す。本製法にて作製したコアシェル型ナノ微粒子は、エタノールにて洗浄したものであり、仮にＰＥＧ４００単体で存在しているものがあるとすれば洗浄過程で取り除かれる。図２（上）の測定結果は、ＣＯＣ、ＣＯや、ＣＣ等の飽和炭化水素に特有の結合のピークを有していることから、ＰＥＧ４００を用いて作製したＣｏＦｅ２Ｏ４をコアとするコアシェル型ナノ微粒子は、ＰＥＧ４００に由来するＰＥＧの主鎖がＣｏＦｅ２Ｏ４のコアと化学結合しているものと考えられる。(FT-IR measurement result)
Subsequently, the FT-IR measurement of the obtained core-shell type nanoparticles was performed. The FT-IR measurement result of the core-shell type nanoparticles of Example 1 is shown in FIG. 2 (top). The FT-IR measurement results of the CoFe 2 O 4 standard sample are shown in FIG. 2 (bottom). The core-shell type nanoparticles produced by this production method are washed with ethanol, and if any of the PEG400 alone exists, it is removed in the washing process. Since the measurement result in FIG. 2 (top) has a bond peak peculiar to saturated hydrocarbons such as COC, CO, and CC, a core shell having CoFe 2 O 4 produced using PEG400 as a core. It is considered that the main chain of PEG derived from PEG400 is chemically bonded to the core of CoFe 2 O 4 in the type nanoparticles.
（ＭＳ測定結果）
さらに、ＰＥＧ４００を用いて作製した実施例１のコアシェル型ナノ微粒子について、ＤＨＢをマトリクスとする質量分析測定を行った。測定結果を図３に示す。ピーク間隔が４４であるＰＥＧ４００由来のピークが観測されたことからも、本コアシェル型ナノ微粒子は、ＰＥＧ４００に由来するＰＥＧの主鎖が化学結合していることが確認された。ナノ微粒子とＰＥＧとの結合はレーザーによって切れたと考えられる。ピーク間隔が４４であるということは、ＰＥＧ４００の分子内の結合は反応によって不飽和結合などに形を変えていないことがわかる。(MS measurement result)
Further, the core-shell type nanoparticles of Example 1 prepared using PEG400 were subjected to mass spectrometric measurement using DHB as a matrix. The measurement results are shown in FIG. From the fact that peaks derived from PEG400 with a peak interval of 44 were observed, it was confirmed that the main chain of PEG derived from PEG400 was chemically bonded to the core-shell type nanoparticles. It is considered that the bond between the nanoparticles and PEG was broken by the laser. The fact that the peak interval is 44 indicates that the intramolecular bond of PEG400 does not change into an unsaturated bond or the like due to the reaction.
（二次粒径測定結果）
ＰＥＧ４００を用いて作製したＣｏＦｅ２Ｏ４ナノ微粒子の二次粒径はモード径が４７５ｎｍ、メジアン径は４３０ｎｍであった。比較例のナノ微粒子の二次粒径（モード径３．６３μｍ、メジアン径２．２７μｍ）に比べて液中でのコロイド径は１桁ほど小さくなっており、分散性に優れることを確認できた。(Secondary particle size measurement result)
The secondary particle size of the CoFe 2 O 4 nanoparticles prepared using PEG400 had a mode diameter of 475 nm and a median diameter of 430 nm. Compared with the secondary particle size (mode diameter 3.63 μm, median diameter 2.27 μm) of the nanoparticles of the comparative example, the colloid diameter in the liquid was about an order of magnitude smaller, and it was confirmed that the dispersibility was excellent. ..
［実施例２］
＜ＰＥＧ４００末端の水酸基のカルボキシル化＞
純水１５０ｍｌに実施例１で得られたＣｏＦｅ２Ｏ４ナノ微粒子の粉末０．２ｇを入れ、４ｍｌの過酸化水素水溶液試薬（３０Ｗ／Ｖ％）を入れ、室温で１０ｈ撹拌した。純水で３回洗浄してから乾燥し、粉末とした。[Example 2]
<Carboxylation of hydroxyl group at the end of PEG400>
0.2 g of the powder of CoFe 2 O 4 nanoparticles obtained in Example 1 was added to 150 ml of pure water, 4 ml of a hydrogen peroxide aqueous solution reagent (30 W / V%) was added, and the mixture was stirred at room temperature for 10 hours. After washing with pure water three times, it was dried to obtain a powder.
（ＦＴ−ＩＲ測定結果）
得られた実施例２のコアシェル型ナノ微粒子のＦＴ−ＩＲ測定をした。実施例２のコアシェル型ナノ微粒子のＦＴ−ＩＲ測定結果を図４（上）に示す。比較のため、実施例１のコアシェル型ナノ微粒子のＦＴ−ＩＲ測定結果を図４（下）に示す。図４（上）の測定結果から、１６６０ｎｍのケトン由来のピーク、２５００〜３３００ｎｍの短波長方向に広がったＯＨ由来のピークが観測されたことによって、過酸化水素が酸化剤として働いて、ＰＥＧ４００末端の水酸基のカルボキシル化が、式（５）に沿って正しく行われたことが確認できた。(FT-IR measurement result)
The FT-IR measurement of the obtained core-shell type nanoparticles of Example 2 was performed. The FT-IR measurement result of the core-shell type nanoparticles of Example 2 is shown in FIG. 4 (top). For comparison, the FT-IR measurement results of the core-shell type nanoparticles of Example 1 are shown in FIG. 4 (bottom). From the measurement results in FIG. 4 (top), a peak derived from a ketone at 1660 nm and a peak derived from OH spreading in the short wavelength direction of 2500 to 3300 nm were observed, so that hydrogen peroxide acted as an oxidizing agent and the PEG400 terminal. It was confirmed that the carboxylation of the hydroxyl group of No. 1 was correctly performed according to the formula (5).
［実施例３］
＜ＰＥＧ４００へのグルコサミンの化学修飾＞
純水１５０ｍｌに実施例２で得られたコアシェル型ナノ微粒子の粉末０．０５ｇと、グルコサミン塩酸塩０．５ｇを入れ、リービッヒ冷却をしながら１３０℃で２５．５ｈ攪拌加熱した。その後、純水で洗浄してから乾燥し、粉末にした。[Example 3]
<Chemical modification of glucosamine to PEG400>
0.05 g of the core-shell type nanoparticles powder obtained in Example 2 and 0.5 g of glucosamine hydrochloride were added to 150 ml of pure water, and the mixture was stirred and heated at 130 ° C. for 25.5 hours while cooling with Liebig. Then, it was washed with pure water, dried, and made into a powder.
（ＦＴ−ＩＲ測定結果）
得られたナノ微粒子についてＦＴ−ＩＲ測定をした。実施例３のナノ微粒子のＦＴ−ＩＲ測定結果を図５（上）に示す。比較のため、実施例２のナノ微粒子のＦＴ−ＩＲ測定結果を図５（下）に示す。(FT-IR measurement result)
FT-IR measurement was performed on the obtained nanoparticles. The FT-IR measurement result of the nanoparticles of Example 3 is shown in FIG. 5 (top). For comparison, the FT-IR measurement results of the nanoparticles of Example 2 are shown in FIG. 5 (bottom).
１６００ｎｍ付近のピークに関して反応後にピークがブロードに、さらに頂点が左に移動していることがわかる。これは、コアシェル型ナノ微粒子の側のＣＯＯＨ基とグルコサミンのアミノ基が脱水縮合してアミド結合が形成されたことで、１５５０ｎｍ付近のピークが重ね合わせられたことによるものと考えられる。また、２８８０ｎｍ付近のＣＨのピーク強度が上がっていること、様々な状態でＯＨを持つ糖の影響によってＯＨのピークが広がっていることから、糖が修飾されたと考えることができる。以上の図５（上）の測定結果から、式（６）に沿って、ＰＥＧ４００へのグルコサミンの化学修飾が正しく行われたことを確認できた。 It can be seen that for the peak near 1600 nm, the peak moves to broad after the reaction, and the apex moves to the left. It is considered that this is because the COOH group on the side of the core-shell type nanoparticles and the amino group of glucosamine were dehydrated and condensed to form an amide bond, and the peaks around 1550 nm were overlapped. Further, since the peak intensity of CH near 2880 nm is increased and the peak of OH is widened due to the influence of the sugar having OH in various states, it can be considered that the sugar is modified. From the above measurement results in FIG. 5 (top), it was confirmed that the chemical modification of glucosamine to PEG400 was correctly performed according to the formula (6).
実施例３のナノ微粒子は、シェルがグルコース骨格を有するグルコサミンで化学修飾されているので、腫瘍組織中に集積しやすい性質が得られると期待できる。また、実施例３のナノ微粒子は、ＭＦｅ２Ｏ４からなるコアを有しているので、磁気ハイパーサーミア（癌温熱療法）への利用も期待できる。Since the shell of the nanoparticles of Example 3 is chemically modified with glucosamine having a glucose skeleton, it can be expected that the nanoparticles easily accumulate in the tumor tissue. Further, since the nanoparticles of Example 3 have a core made of MFe 2 O 4 , it can be expected to be used for magnetic hyperthermia (cancer hyperthermia).
［実施例４］
（材料）
・培地：ＤＭＥＭ ｃｏｎｔａｉｎｉｎｇ １０％ （ｖｏｌ/ｖｏｌ） ｃａｌｆ ｓｅｒｕｍを用いた。以下、培地（ＤＭＥＭ／１０％ＣＳ）という。
・ＨｅＬａ細胞：理研セルバンクから入手したＨｅＬａ細胞を、培地（ＤＭＥＭ／１０％ＣＳ）で継代培養していたものを、３５ｍｍ ｇｌａｓｓ ｂｏｔｔｏｍ ｄｉｓｈに播種した後、２４ｈ後のものを実験に使用した。播種時の細胞数は、２×１０５ ｃｅｌｌｓ/ ｄｉｓｈであった。[Example 4]
(material)
-Medium: DMEM conditioning 10% (vol / vol) calf serum was used. Hereinafter, it is referred to as a medium (DMEM / 10% CS).
-HeLa cells: HeLa cells obtained from RIKEN cell bank were subcultured in a medium (DMEM / 10% CS), seeded in 35 mm glass bottom dish, and 24 hours later were used in the experiment. The number of cells at the time of seeding was 2 × 10 5 cells / dish.
（ナノ微粒子懸濁液の調製）
実施例３のナノ微粒子の粉末にＰＢＳ（ｐＨ７．４）を添加し、超音波処理することによって均一な懸濁液とした後、適宜ＰＢＳ（ｐＨ７．４）で希釈することによって、最終的に１０ｍｇ/ｍｌの濃度の懸濁液を調製した。更に、培地（ＤＭＥＭ／１０％ＣＳ）で１００倍希釈したナノ微粒子懸濁液を調製した。(Preparation of nanoparticle suspension)
PBS (pH 7.4) was added to the powder of the nanoparticles of Example 3, and the suspension was made uniform by sonication, and then diluted with PBS (pH 7.4) as appropriate to finally obtain the suspension. A suspension having a concentration of 10 mg / ml was prepared. Further, a nanoparticle suspension diluted 100-fold with medium (DMEM / 10% CS) was prepared.
（実験）
ｄｉｓｈ上のＨｅＬａ細胞に対して、培地（ＤＭＥＭ／１０％ＣＳ）で１００倍希釈したナノ微粒子懸濁液を添加し、３７℃のＣＯ２インキュベータで２４ｈ静置した。その後、２．５％（ｗ/ｖ）グルタルアルデヒド／ＰＢＳ（ｐＨ７．４）中で室温１ｈ固定した後、ＴＥＭ観察用のサンプル調製を行った。ＴＥＭ観察には、ＪＥＭ−１４００（日本電子株式会社）を使用した。(Experiment)
To HeLa cells on the dish, a nanoparticle suspension diluted 100-fold with medium (DMEM / 10% CS) was added, and the mixture was allowed to stand in a CO 2 incubator at 37 ° C. for 24 hours. Then, after fixing in 2.5% (w / v) glutaraldehyde / PBS (pH 7.4) at room temperature for 1 h, a sample for TEM observation was prepared. JEM-1400 (JEOL Ltd.) was used for TEM observation.
図６は、実施例３のナノ微粒子が、ＨｅＬａ細胞内に取り込まれたことを示すＴＥＭ像である。図６に示すように、エンドソーム／リソソーム内に、実施例３のナノ微粒子の凝集体を確認でき、滴下から２４時間後には実施例３のナノ微粒子が、ＨｅＬａ細胞内に取り込まれたことが確認できた。
実施例３のナノ微粒子ががん細胞内に取り込まれていることから、シェルがグルコース又はグルコース誘導体で化学修飾されているナノ微粒子を有効成分として含有する抗腫瘍剤は、磁気ハイパーサーミアへの利用が期待される。FIG. 6 is a TEM image showing that the nanoparticles of Example 3 were taken up into HeLa cells. As shown in FIG. 6, aggregates of the nanoparticles of Example 3 could be confirmed in endosomes / lysosomes, and it was confirmed that the nanoparticles of Example 3 were taken up into HeLa cells 24 hours after the dropping. did it.
Since the nanoparticles of Example 3 are incorporated into cancer cells, an antitumor agent containing nanoparticles whose shell is chemically modified with glucose or a glucose derivative as an active ingredient can be used for magnetic hyperthermia. Be expected.
［実施例５］
＜ＰＥＧ４００を用いたＭｎ０．８Ｚｎ０．２Ｆｅ２Ｏ４ナノ微粒子の作製＞
５０ｍｌのＰＥＧ４００の中で、５ｍｍｏｌのＦｅＣｌ２・４Ｈ２Ｏ、２．０ｍｍｏｌのＭｎＣｌ２・４Ｈ２Ｏ、０．５ｍｍｏｌのＺｎＣｌ２（無水物）、及び１５ｍｍｏｌの水酸化ナトリウムを７０℃で１時間混合して、中和反応させた。反応液を、反応容器のまま箱型オーブンの中に入れ、２００℃で１６時間加熱し、炉冷後の反応液に対して、遠心分離機（３５００ｒｐｍ, １０ｍｉｎ）で沈殿させ、エタノールで３回洗浄する工程を３回繰り返した。乾燥して、Ｍｎ０．８Ｚｎ０．２Ｆｅ２Ｏ４をコアとするコアシェル型ナノ微粒子の粉末を得た。得られたコアシェル型ナノ微粒子の磁性体部分の平均粒径（一次粒子径）は１２ｎｍであった。ＦＴ-ＩＲ, ＴＧ-ＤＴＡ（示差熱分析）などから洗浄後も十分な量のＰＥＧが存在することが確認できたことから、ＰＥＧが粒子周囲をコーティングしていると考えられる。[Example 5]
<Preparation of Mn 0.8 Zn 0.2 Fe 2 O 4 nanoparticles using PEG400>
Among 50ml of PEG400, FeCl 2 · 4H 2 O in 5mmol, MnCl 2 · 4H 2 O , ZnCl 2 ( anhydrous) of 0.5mmol of 2.0 mmol, and 1 hour at 70 ° C. of sodium hydroxide of 15mmol It was mixed and neutralized. The reaction solution is placed in a box-shaped oven as it is in the reaction vessel, heated at 200 ° C. for 16 hours, precipitated in the reaction solution after cooling in a furnace with a centrifuge (3500 rpm, 10 min), and 3 times with ethanol. The washing step was repeated 3 times. Drying gave a powder of core-shell type nanoparticles having Mn 0.8, Zn 0.2, Fe 2 O 4 as a core. The average particle size (primary particle size) of the magnetic part of the obtained core-shell type nanoparticles was 12 nm. Since it was confirmed from FT-IR, TG-DTA (differential thermal analysis), etc. that a sufficient amount of PEG was present even after washing, it is considered that the PEG coats the periphery of the particles.
さらにグルコース修飾によりがん細胞への取り込みも変化することからも、粒子を包含したＰＥＧにグルコースが修飾され、粒子の取り込み量に差が出ていると考えられる。１つのコア粒子に約６０００個のＰＥＧが付いていると考えられ、一周、２ｎｍ程度の薄さで覆っていると考えられる。 Furthermore, since glucose modification also changes the uptake into cancer cells, it is considered that glucose is modified in PEG containing particles, and the amount of uptake of particles is different. It is considered that about 6000 PEGs are attached to one core particle, and it is considered that the circumference is covered with a thinness of about 2 nm.
［実施例５−２］
５０ｍｌのＰＥＧ４００の中で、５ｍｍｏｌのＦｅＣｌ２・４Ｈ２Ｏ、２．０ｍｍｏｌのＭｎＣｌ２・４Ｈ２Ｏ、０．５ｍｍｏｌのＺｎＣｌ２（無水物）、及び１５ｍｍｏｌの水酸化ナトリウムを７０℃で１時間混合して、中和反応させた。反応液を、反応容器のまま箱型オーブンの中に入れ、１６０℃で１６時間加熱し、炉冷後の反応液に対して、遠心分離機（３５００ｒｐｍ, １０ｍｉｎ）で沈殿させ、エタノールで２回、純水で２回洗浄した。その後乾燥させ、Ｍｎ０．８Ｚｎ０．２Ｆｅ２Ｏ４をコアとするコアシェル型ナノ微粒子の粉末を得た。得られたコアシェル型ナノ微粒子の磁性体部分の平均粒径（一次粒子径）は６ｎｍであった。
作製時に加える水量が少ないほど粒径分布が狭くなるという傾向があり、ほぼ単分散の平均粒径６ｎｍのナノ微粒子を得ることができた。[Example 5-2]
Among 50ml of PEG400, FeCl 2 · 4H 2 O in 5mmol, MnCl 2 · 4H 2 O , ZnCl 2 ( anhydrous) of 0.5mmol of 2.0 mmol, and 1 hour at 70 ° C. of sodium hydroxide of 15mmol It was mixed and neutralized. The reaction solution is placed in a box-shaped oven as it is in the reaction vessel, heated at 160 ° C. for 16 hours, precipitated in the reaction solution after cooling in a furnace with a centrifuge (3500 rpm, 10 min), and twice with ethanol. , Washed twice with pure water. Then, it was dried to obtain a powder of core-shell type nanoparticles having Mn 0.8, Zn 0.2, Fe 2 O 4 as a core. The average particle size (primary particle size) of the magnetic part of the obtained core-shell type nanoparticles was 6 nm.
The smaller the amount of water added during production, the narrower the particle size distribution tends to be, and it was possible to obtain nanoparticles with an average particle size of 6 nm, which are almost monodisperse.
［実施例５−３］
５０ｍｌのＰＥＧ４００及び４ｍｌの純水の混合液の中で、５ｍｍｏｌのＦｅＣｌ２・４Ｈ２Ｏ、２．０ｍｍｏｌのＭｎＣｌ２・４Ｈ２Ｏ、０．５ｍｍｏｌのＺｎＣｌ２（無水物）、及び１５ｍｍｏｌの水酸化ナトリウムを７０℃で１時間混合して、中和反応させた。反応液を、反応容器のまま箱型オーブンの中に入れ、１６０℃で１６時間加熱し、炉冷後の反応液に対して、遠心分離機（３５００ｒｐｍ, １０ｍｉｎ）で沈殿させ、エタノールで２回、純水で２回洗浄した。その後乾燥させ、Ｍｎ０．８Ｚｎ０．２Ｆｅ２Ｏ４をコアとするコアシェル型ナノ微粒子の粉末を得た。得られたコアシェル型ナノ微粒子の磁性体部分の平均粒径（一次粒子径）は１０ｎｍであった。コア部分の酸化物の１次粒径は、６〜３０ｎｍで、作製条件（水の量、焼成温度）で制御することができる。[Example 5-3]
Among mixed liquid of pure water PEG400 and 4ml of 50ml, FeCl 2 · 4H 2 O in 5mmol, MnCl 2 · 4H 2 O , ZnCl 2 ( anhydrous) of 0.5mmol of 2.0 mmol, and 15mmol of water Sodium oxide was mixed at 70 ° C. for 1 hour for a neutralization reaction. The reaction solution is placed in a box-shaped oven as it is in the reaction vessel, heated at 160 ° C. for 16 hours, precipitated in the reaction solution after cooling in a furnace with a centrifuge (3500 rpm, 10 min), and twice with ethanol. , Washed twice with pure water. Then, it was dried to obtain a powder of core-shell type nanoparticles having Mn 0.8, Zn 0.2, Fe 2 O 4 as a core. The average particle size (primary particle size) of the magnetic part of the obtained core-shell type nanoparticles was 10 nm. The primary particle size of the oxide in the core portion is 6 to 30 nm, and can be controlled by the production conditions (amount of water, firing temperature).
［実施例６］
実施例５で得られたコアシェル型ナノ微粒子について、更に、実施例２と同様に、ＰＥＧ４００末端の水酸基のカルボキシル化と、実施例３と同様に、ＰＥＧ４００へのグルコサミンの化学修飾を行った。[Example 6]
The core-shell type nanoparticles obtained in Example 5 were further subjected to carboxylation of the hydroxyl group at the terminal of PEG400 as in Example 2 and chemical modification of glucosamine to PEG400 as in Example 3.
（ＦＴ−ＩＲ測定結果）
グルコサミンで化学修飾された実施例６のナノ微粒子のＦＴ−ＩＲ測定をした。ＭｎＦｅ２Ｏ４標準試料のＦＴ−ＩＲ測定結果を図７（上）に示す。実施例５のＰＥＧ４００を用いたＭｎ０．８Ｚｎ０．２Ｆｅ２Ｏ４ナノ微粒子のＦＴ−ＩＲ測定結果を図７（中）に示す。１１０５ ± ５５ｃｍ−１のＣ−Ｏ−Ｃ逆対称伸縮運動、１４８５ ± １５ｃｍ−１のＣＨ２対称変角振動、３４００ ± ２００ｃｍ−１のＯ−Ｈ間伸縮運動が観測された。実施例６のグルコサミンで化学修飾後のナノ微粒子のＦＴ−ＩＲ測定結果を図７（下）に示す。１０９５ ± ２５ｃｍ−１のＣ−Ｏ−Ｃ伸縮運動、１１７５ ± ２５ｃｍ−１のＣ−Ｏ伸縮運動、１２６５ ± ５５ｃｍ−１のＣ−Ｏ伸縮、Ｏ−Ｈ変角振動、１６７０ ± ４０ｃｍ−１のアミド結合によるＣ＝Ｏ伸縮、３４００ ± ２００ｃｍ−１のＯ−Ｈ間伸縮運動が観測された。(FT-IR measurement result)
The FT-IR measurement of the nanoparticles of Example 6 chemically modified with glucosamine was performed. The FT-IR measurement results of the MnFe 2 O 4 standard sample are shown in FIG. 7 (top). The FT-IR measurement results of Mn 0.8 Zn 0.2 Fe 2 O 4 nanoparticles using PEG400 of Example 5 are shown in FIG. 7 (middle). 1105 ± 55 cm -1 COC inverse symmetric stretching motion, 1485 ± 15 cm -1 CH 2 symmetric angular vibration, and 3400 ± 200 cm -1 OH stretching motion were observed. The FT-IR measurement results of the nanoparticles chemically modified with glucosamine of Example 6 are shown in FIG. 7 (bottom). 1095 ± 25 cm -1 C-OC telescopic movement, 1175 ± 25 cm -1 C-O telescopic movement, 1265 ± 55 cm -1 CO expansion and contraction, OH angular vibration, 1670 ± 40 cm -1 C = O expansion and contraction due to the amide bond, 3400 ± 200 cm -1 between O and H expansion and contraction movements were observed.
［実施例７］
＜ＰＥＧ２０００を用いたＣｏＦｅ２Ｏ４ナノ微粒子の作製＞
１／３００ｍｏｌのＦｅＣｌ２・４Ｈ２Ｏ、及び１／６００ｍｏｌのＣｏＣｌ２・６Ｈ２Ｏを、１ｍｌの水に溶解させ、５５℃で液状にした３０ｇのＰＥＧ２０００に加えた。１０時間撹拌させた後、０．５ｍｌの水に溶解させたＮａＯＨを加えた。１０時間撹拌させた後、１６０℃で１６時間加熱した。遠心分離してエタノール、水で洗浄し、５０℃で乾燥させて、ＣｏＦｅ２Ｏ４をコアとするコアシェル型ナノ微粒子の粉末を得た。得られたコアシェル型ナノ微粒子の磁性体部分の平均粒径（一次粒子径）は２７ｎｍであった。[Example 7]
<Preparation of CoFe 2 O 4 nanoparticles using PEG2000>
FeCl 2 · 4H 2 O in 1/300 mol, and CoCl 2 · 6H 2 O in 1 / 600mol, dissolved in water 1 ml, was added to PEG2000 of 30g was a liquid at 55 ° C.. After stirring for 10 hours, NaOH dissolved in 0.5 ml of water was added. After stirring for 10 hours, the mixture was heated at 160 ° C. for 16 hours. The mixture was centrifuged, washed with ethanol and water, and dried at 50 ° C. to obtain a powder of core-shell type nanoparticles having CoFe 2 O 4 as a core. The average particle size (primary particle size) of the magnetic part of the obtained core-shell type nanoparticles was 27 nm.
（ＸＲＤ分析結果）
ＸＲＤ分析の結果を図８に示す。指数づけしたピークから、単相のスピネル構造を持ったＣｏＦｅ２Ｏ４ [No. 000-022-1086、Name: Cobalt Iron Oxide、Quality Mark: S、Cell (8.392, 8.392, 8.392)] が同定できたことから、目的のＣｏＦｅ２Ｏ４が作成できたことを確認した。湿式混合法で作ったＣｏＦｅ２Ｏ４をコアとするコアシェル型ナノ微粒子のＸＲＤ分析の結果の図１（上）に比べて、図８のＰＥＧ２０００を用いたコアシェル型ナノ微粒子のＸＲＤ分析の結果は、２０〜３０°の位置にアモルファスのブロードなピークがないことが確認された。(XRD analysis result)
The result of XRD analysis is shown in FIG. From the indexed peak, CoFe 2 O 4 [No. 000-022-1086, Name: Cobalt Iron Oxide, Quality Mark: S, Cell (8.392, 8.392, 8.392)] having a single-phase spinel structure can be identified. Therefore, it was confirmed that the target CoFe 2 O 4 could be prepared. Compared with the result of XRD analysis of core-shell type nanoparticles having CoFe 2 O 4 as a core produced by the wet mixing method, the result of XRD analysis of core-shell type nanoparticles using PEG2000 in FIG. 8 is It was confirmed that there was no amorphous broad peak at the position of 20 to 30 °.
（ＦＴ−ＩＲ測定結果）
続いて、得られたコアシェル型ナノ微粒子のＦＴ−ＩＲ測定をした。実施例７のコアシェル型ナノ微粒子のＦＴ−ＩＲ測定結果を図９に、実線「２０００」に示す。図９の太線「Ｓｔｄ．（ＭｎＦｅ）」は、ＭｎＦｅ２Ｏ４標準試料のＦＴ−ＩＲ測定結果であり、図９の点線「４００」は、実施例１のＰＥＧ４００を用いたＣｏＦｅ２Ｏ４ナノ微粒子のＦＴ−ＩＲ測定結果である。
実施例７のコアシェル型ナノ微粒子からは、１１０５ ± ５５ｃｍ−１のＣ−Ｏ−Ｃ逆対称伸縮運動、１４８５ ± １５ｃｍ−１のＣＨ２対称変角振動、３４００ ± ２００ｃｍ−１のＯ−Ｈ間伸縮運動が観測された。
実施例７のコアシェル型ナノ微粒子のＦＴ−ＩＲ測定結果は、ＣＯＣ、ＣＨ２や、Ｏ−Ｈ等の飽和炭化水素に特有の結合のピークを有していることから、ＰＥＧ２０００を用いて作製したＣｏＦｅ２Ｏ４をコアとするコアシェル型ナノ微粒子は、ＰＥＧ２０００に由来するＰＥＧの主鎖がＣｏＦｅ２Ｏ４のコアと化学結合しているものと考えられる。(FT-IR measurement result)
Subsequently, the FT-IR measurement of the obtained core-shell type nanoparticles was performed. The FT-IR measurement result of the core-shell type nanoparticles of Example 7 is shown in FIG. 9 by the solid line “2000”. The thick line “Std. (MnFe)” in FIG. 9 is the FT-IR measurement result of the MnFe 2 O 4 standard sample, and the dotted line “400” in FIG. 9 is the CoFe 2 O 4 nano using the PEG 400 of Example 1. It is the FT-IR measurement result of the fine particles.
From the core-shell type nanoparticles of Example 7, 1105 ± 55 cm -1 COC inverse symmetric stretching motion, 1485 ± 15 cm -1 CH 2 symmetric angular vibration, and 3400 ± 200 cm -1 OH. Stretching motion was observed.
The FT-IR measurement result of the core-shell type nanoparticles of Example 7 was prepared using PEG2000 because it has a bond peak peculiar to saturated hydrocarbons such as COC, CH 2 and OH. core-shell nanoparticles of the CoFe 2 O 4 and the core is believed to the main chain of the PEG derived from PEG2000 is bound core and chemistry of CoFe 2 O 4.
１・・・ナノ微粒子、１０・・・コア、２０・・・シェル、Ｇｌｃ・・・グルコース、Ｇｌｃ’・・・グルコース誘導体 1 ... Nanoparticles, 10 ... Core, 20 ... Shell, Glc ... Glucose, Glc'... Glucose derivative
Claims (8)
前記コアを覆うシェルと、を有し、
前記シェルがグルコース又はグルコース誘導体で化学修飾されているナノ微粒子。A core composed of MFe 2 O 4 (in MFe 2 O 4 above, M represents a transition metal) and
With a shell covering the core,
Nanoparticles in which the shell is chemically modified with glucose or a glucose derivative.
前記官能基にグルコース又はグルコース誘導体を反応させる工程と、を有する、請求項１〜４のうちいずれか一項に記載のナノ微粒子の製造方法。A step of forming core-shell type nanoparticles having a core composed of MFe 2 O 4 (in the MFe 2 O 4 , M represents a transition metal) and a shell containing a functional group covering the core.
The method for producing nanoparticles according to any one of claims 1 to 4, which comprises a step of reacting a glucose or a glucose derivative with the functional group.
前記ポリアルキレングリコールの末端のヒドロキシメチル基を酸化させて、カルボキシル基にする工程と、
前記カルボキシル基にグルコース又はグルコース誘導体を反応させる工程と、を有する、請求項５に記載のナノ微粒子の製造方法。(In the MFe 2 O 4, M represents a transition metal) MFe 2 core consisting of O 4 forming the, core-shell nanoparticles having a shell of a polyalkylene glycol to cover the core,
The step of oxidizing the hydroxymethyl group at the terminal of the polyalkylene glycol to form a carboxyl group, and
The method for producing nanoparticles according to claim 5, further comprising a step of reacting glucose or a glucose derivative with the carboxyl group.
前記水酸化物を含む反応物を加熱し焼成する工程と、を有するコアシェル型ナノ微粒子の製造方法。A step of heating and mixing polyalkylene glycol, a chloride of a transition metal containing iron, and an alkali to obtain a hydroxide, and
A method for producing core-shell type nanoparticles, which comprises a step of heating and firing a reactant containing a hydroxide.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018038989 | 2018-03-05 | ||
| JP2018038989 | 2018-03-05 | ||
| PCT/JP2019/008494 WO2019172213A1 (en) | 2018-03-05 | 2019-03-05 | Nanoparticle, nanoparticle production method, and anti-tumor agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2019172213A1 true JPWO2019172213A1 (en) | 2021-02-18 |
| JP7401864B2 JP7401864B2 (en) | 2023-12-20 |
Family
ID=67846162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020505032A Active JP7401864B2 (en) | 2018-03-05 | 2019-03-05 | Nanoparticles, methods for producing nanoparticles, and antitumor agents |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP7401864B2 (en) |
| WO (1) | WO2019172213A1 (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63258896A (en) * | 1987-04-15 | 1988-10-26 | Ajinomoto Co Inc | Modified interleukin-2 |
| JP2007526230A (en) * | 2003-06-25 | 2007-09-13 | エラン ファーマシューティカルズ，インコーポレイテッド | Methods and compositions for treating rheumatoid arthritis |
| JP2013256405A (en) * | 2012-06-13 | 2013-12-26 | Yokohama National Univ | Ni-Zn-BASED FERRITE MAGNETIC NANOPARTICLE FOR THERMOTHERAPY, AND DRUG-BOUND COMPLEX FOR THERMOTHERAPY USING THE SAME |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10258896A (en) * | 1997-03-14 | 1998-09-29 | Aisan Ind Co Ltd | Feed valve for effervescent beverage |
-
2019
- 2019-03-05 JP JP2020505032A patent/JP7401864B2/en active Active
- 2019-03-05 WO PCT/JP2019/008494 patent/WO2019172213A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63258896A (en) * | 1987-04-15 | 1988-10-26 | Ajinomoto Co Inc | Modified interleukin-2 |
| JP2007526230A (en) * | 2003-06-25 | 2007-09-13 | エラン ファーマシューティカルズ，インコーポレイテッド | Methods and compositions for treating rheumatoid arthritis |
| JP2013256405A (en) * | 2012-06-13 | 2013-12-26 | Yokohama National Univ | Ni-Zn-BASED FERRITE MAGNETIC NANOPARTICLE FOR THERMOTHERAPY, AND DRUG-BOUND COMPLEX FOR THERMOTHERAPY USING THE SAME |
Non-Patent Citations (3)
| Title |
|---|
| HSU, CHIEN-WEI ET AL.: "Glucose-Modified Silicon Nanoparticles for Cellular Imaging", CHEMPLUSCHEM, vol. 82, JPN6019011542, 2017, pages 660 - 667, XP055638332, ISSN: 0004977459, DOI: 10.1002/cplu.201700054 * |
| ISSA, BASHAR ET AL.: "PEG Coating Reduces NMR Relaxivity of Mn0.5Zn0.5Gd0.02Fe1.98O4 Hyperthermia Nanoparticles", JOURNAL OF MAGNETIC RESONANCE IMAGING, vol. 34, JPN6019011540, 2011, pages 1192 - 1198, XP055209060, ISSN: 0004977458, DOI: 10.1002/jmri.22703 * |
| TIAN, BAOCHENG ET AL.: "N-Acetyl-D-glucosamine decorated polymeric nanoparticles for targeted delivery of doxorubicin:Synthe", COLLOIDS AND SURFACES B:BIOINTERFACES, vol. 130, JPN6019011544, 2015, pages 246 - 254, XP029244226, ISSN: 0004977460, DOI: 10.1016/j.colsurfb.2015.04.019 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019172213A1 (en) | 2019-09-12 |
| JP7401864B2 (en) | 2023-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zheng et al. | X-ray recharged long afterglow luminescent nanoparticles MgGeO 3: Mn 2+, Yb 3+, Li+ in the first and second biological windows for long-term bioimaging | |
| Escudero et al. | Microwave-assisted synthesis of biocompatible europium-doped calcium hydroxyapatite and fluoroapatite luminescent nanospindles functionalized with poly (acrylic acid) | |
| Yoon et al. | Surface modification of exfoliated layered gadolinium hydroxide for the development of multimodal contrast agents for MRI and fluorescence imaging | |
| Xu et al. | Layered bismuth oxyhalide nanomaterials for highly efficient tumor photodynamic therapy | |
| KR101014246B1 (en) | pH SENSITIVE METAL NONAPARTICLES AND MANUFACTURING MEHTODS THEREOF | |
| TWI321133B (en) | Folate-receptor-targeting iron oxide nanoparticles coated with poly(ethylene glycol) | |
| Zheng et al. | Multifunctional graphene quantum dots-conjugated titanate nanoflowers for fluorescence-trackable targeted drug delivery | |
| Rodriguez-Liviano et al. | Ionic liquid mediated synthesis and surface modification of multifunctional mesoporous Eu: GdF3 nanoparticles for biomedical applications | |
| JP6820154B2 (en) | Luminescent nanoparticles, cell detection methods using them, animal treatment methods, medical devices, cell visualization methods, and cell damage mitigation methods | |
| JP6739435B2 (en) | SiO2-layered double hydroxide microspheres and method for making the same | |
| WO2021187492A1 (en) | Complex between silicate-based substrate and rare earth element compound, light-emitting nano particles, cell detection method, animal treatment method, medical device, and method for producing complex between silicate-based substrate and rare earth element compound | |
| Wang et al. | Optimizing the silanization of thermally-decomposed iron oxide nanoparticles for efficient aqueous phase transfer and MRI applications | |
| Wang et al. | An efficient strategy to synthesize a multifunctional ferroferric oxide core@ dye/SiO 2@ Au shell nanocomposite and its targeted tumor theranostics | |
| Du et al. | Decoration of upconversion nanocrystals with metal sulfide quantum dots by a universal in situ controlled growth strategy | |
| KR101097907B1 (en) | Surface-modified Layered Gadolinium Hydroxide, Process of Preparing the Same and MRI Contrast Agent Including the Same | |
| CN108785690B (en) | Tumor diagnosis and treatment integrated nano material and preparation method thereof | |
| CN109983080A (en) | The ligand substituting method of surfaces of metal nanoparticles | |
| JPWO2019172213A1 (en) | Nanoparticles, methods for producing nanoparticles, and antitumor agents | |
| Klimkevicius et al. | Effect of cationic brush-type copolymers on the colloidal stability of GdPO4 particles with different morphologies in biological aqueous media | |
| WO2009107046A1 (en) | Preparation of nanoparticles from metal salts or metal oxides | |
| Marchesi et al. | Novel paramagnetic clays obtained through intercalation of Gd 3+-complexes | |
| Sarabi et al. | Polyrotaxane capped quantum dots as new candidates for cancer diagnosis and therapy | |
| Sichamnan et al. | Fabrication of biocompatible magneto-fluorescence nanoparticles as a platform for fluorescent sensor and magnetic hyperthermia applications | |
| Chawda et al. | Synthesis of gadolinium oxide nanocuboids for in vitro bioimaging applications | |
| KR101131724B1 (en) | Silica Nanosphere, Process of Preparing the Same and MRI Contrast Agent Including the Same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD01 | Notification of change of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7426 Effective date: 20200807 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200730 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20200807 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220215 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230131 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230316 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230606 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230803 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231031 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231129 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7401864 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |